No products in the cart.
Pre-made Mirvetuximab benchmark antibody ( Whole mAb ADC, anti-FOLR1 therapeutic antibody, Anti-FBP/FOLR/FRalpha/NCFTD Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-349
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Mirvetuximab biosimilar, Whole mAb ADC, Anti-FOLR1 Antibody: Anti-FBP/FOLR/FRalpha/NCFTD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Description. Mirvetuximab Soravtansine is an immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) conjugated, via the disulfide-containing cleavable linker sulfo-SPDB, to the cytotoxic maytansinoid DM4, with potential antineoplastic activity.
| Products Name (INN Index) | Pre-Made Mirvetuximab biosimilar, Whole mAb ADC, Anti-FOLR1 Antibody: Anti-FBP/FOLR/FRalpha/NCFTD therapeutic antibody |
|---|---|
| INN Name | Mirvetuximab |
| Target | FOLR1 |
| Format | Whole mAb ADC |
| Derivation | Chimeric (Mouse/Human) |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | ImmunoGen,National Comprehensive Cancer Network |
| Conditions Approved | NA |
| Conditions Active | Fallopian tube cancer,Ovarian cancer,Peritoneal cancer,Breast cancer,Endometrial cancer |
| Conditions Discontinued | Solid tumours |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | FOLR1 |
| Package |
Previous slide
Next slide
